0.2065

3.94% -0.0009

Apollomics Inc (APLM)

Overview News Price History Why APLM Down? Discussions Forecast

Apollomics Inc stock is currently priced at $0.2065, with a 24-hour trading volume of 728.98K. It has seen a -3.94% decreased in the last 24 hours and a -44.37% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.2103 pivot point. If it approaches the $0.1983 support level, significant changes may occur.

Previous Close:

$0.2056

Open:

$0.2049

24h Volume:

728.98K

Market Cap:

$21.56M

Revenue:

Net Income/Loss:

$-172.60M

P/E Ratio:

-0.0391

EPS:

-5.2851

Net Cash Flow:

$-43.22M

1W Performance:

-8.14%

1M Performance:

-44.37%

6M Performance:

-75.00%

1Y Performance:

-95.95%

1D Range:

$0.1854

$0.2062

52W Range:

$0.1854

$6.20

Apollomics Inc Stock (APLM) Company Profile

Name

Apollomics Inc

Sector

Healthcare (1218)

Industry

Biotechnology (692)

Phone

650 209 4055

Address

989 East Hillsdale Blvd, Suite 220, Foster City

Employee

Twitter

Next Earnings Date

Latest SEC Filings

APLM's Discussions on Twitter

Apollomics Inc Stock (APLM) Latest News

Apollomics, Inc. (NASDAQ:APLM) Sees Large Growth in Short Interest - Defense World

Defense World

Metric Analysis: Apollomics Inc (APLM)'s Key Ratios in the Limelight – DWinneX - The Dwinnex

The Dwinnex

Prepare Yourself for Liftoff: Apollomics Inc (APLM) – Sete News - SETE News

SETE News

APLM’s Stochastic Averages Dip: Analyzing Apollomics Inc’s Stock Performance - The InvestChronicle

The InvestChronicle

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire

GlobeNewswire

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Canada Finance

Yahoo Canada Finance

Apollomics Inc Stock (APLM) Financials Data

Apollomics Inc (APLM) Net Income 2024

APLM net income (TTM) was -$172.60 million for the quarter ending December 31, 2023, a -82.07% decrease year-over-year.

Apollomics Inc (APLM) Cash Flow 2024

APLM recorded a free cash flow (TTM) of -$43.22 million for the quarter ending December 31, 2023, a +15.03% increase year-over-year.

Apollomics Inc (APLM) Earnings per Share 2024

APLM earnings per share (TTM) was -$2.32 for the quarter ending December 31, 2023, a -112.42% decline year-over-year.

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.